EA202191929A1 - Днк-кодируемые моноклональные антитела, нацеленные на pd-1, для лечения и профилактики злокачественного заболевания - Google Patents

Днк-кодируемые моноклональные антитела, нацеленные на pd-1, для лечения и профилактики злокачественного заболевания

Info

Publication number
EA202191929A1
EA202191929A1 EA202191929A EA202191929A EA202191929A1 EA 202191929 A1 EA202191929 A1 EA 202191929A1 EA 202191929 A EA202191929 A EA 202191929A EA 202191929 A EA202191929 A EA 202191929A EA 202191929 A1 EA202191929 A1 EA 202191929A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
dna
prevention
treatment
monoclonal antibodies
Prior art date
Application number
EA202191929A
Other languages
English (en)
Inventor
Дэвид Б. Уэйнер
Альфредо Пералес Пучальт
Original Assignee
Дзе Уистар Инститьют Оф Энэтоми Энд Байолоджи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Уистар Инститьют Оф Энэтоми Энд Байолоджи filed Critical Дзе Уистар Инститьют Оф Энэтоми Энд Байолоджи
Publication of EA202191929A1 publication Critical patent/EA202191929A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В данном документе описана композиция, содержащая последовательность нуклеиновой кислоты, которая кодирует антитело или его фрагмент, которые нацелены на белок программируемой гибели клеток 1 (PD-1). В данном изобретении также предложен способ предотвращения и/или лечения у индивида заболевания, такого как рак, с помощью композиции по изобретению.
EA202191929A 2019-01-11 2020-01-13 Днк-кодируемые моноклональные антитела, нацеленные на pd-1, для лечения и профилактики злокачественного заболевания EA202191929A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962791146P 2019-01-11 2019-01-11
PCT/US2020/013286 WO2020146865A1 (en) 2019-01-11 2020-01-13 Dna monoclonal antibodies targeting pd-1 for the treatment and prevention of cancer

Publications (1)

Publication Number Publication Date
EA202191929A1 true EA202191929A1 (ru) 2021-09-23

Family

ID=71520819

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191929A EA202191929A1 (ru) 2019-01-11 2020-01-13 Днк-кодируемые моноклональные антитела, нацеленные на pd-1, для лечения и профилактики злокачественного заболевания

Country Status (11)

Country Link
US (1) US20220073614A1 (ru)
EP (1) EP3908299A4 (ru)
JP (1) JP2022517228A (ru)
KR (1) KR20210114976A (ru)
CN (1) CN113543800A (ru)
AU (1) AU2020207408A1 (ru)
BR (1) BR112021013008A2 (ru)
CA (1) CA3126073A1 (ru)
EA (1) EA202191929A1 (ru)
MX (1) MX2021008387A (ru)
WO (1) WO2020146865A1 (ru)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101899114A (zh) * 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
GB201419084D0 (en) * 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
CN106939047B (zh) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
EP3964529A1 (en) * 2016-01-22 2022-03-09 Mabquest SA Non-blocking pd1 specific antibodies
MX2018013520A (es) * 2016-05-05 2019-06-10 Univ Pennsylvania Anticuerpos monoclonales de adn dirigidos a moléculas de punto de control.
JP7213799B2 (ja) * 2016-10-10 2023-01-27 ザ ナショナル インスティチュート フォー バイオテクノロジー イン ザ ネゲヴ，リミテッド 非細胞傷害性改変細胞およびその使用

Also Published As

Publication number Publication date
MX2021008387A (es) 2021-10-13
AU2020207408A1 (en) 2021-07-29
WO2020146865A1 (en) 2020-07-16
EP3908299A1 (en) 2021-11-17
CA3126073A1 (en) 2020-07-16
JP2022517228A (ja) 2022-03-07
EP3908299A4 (en) 2022-10-05
BR112021013008A2 (pt) 2021-11-23
KR20210114976A (ko) 2021-09-24
US20220073614A1 (en) 2022-03-10
CN113543800A (zh) 2021-10-22

Similar Documents

Publication Publication Date Title
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
PH12020550967A1 (en) Anti-pd-1 antibodies and methods of treatment
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
MX2024000125A (es) Anticuerpos monoclonales de adn dirigidos a moleculas de punto de control.
EA202091747A1 (ru) Составы антитела b7-h4
MX2021008958A (es) Proteínas de unión a antígeno del receptor gamma anti-il2.
MX2021007572A (es) Anticuerpo anti-pd-1 humanizado y uso del mismo.
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
JOP20210286A1 (ar) جسم مضاد أحادي النسيلة يرتبط نوعياً مع gitr
EA202192587A1 (ru) Антитела к cd73, антитела к pd-l1 и химиотерапия для лечения опухолей
CR20220505A (es) Anticuerpos anti-phf-tau y usos de estos
MX2023013392A (es) Anticuerpos para tratar alfa-sinucleinopatias.
WO2015191590A3 (en) Combination therapies targeting tumor-associated stroma or tumor cells and microtubules
MX2023011339A (es) Anticuerpos anti-tau y usos de estos.
AU2018345715A8 (en) DNA monoclonal antibodies targeting CTLA-4 for the treatment and prevention of cancer
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
EA202191929A1 (ru) Днк-кодируемые моноклональные антитела, нацеленные на pd-1, для лечения и профилактики злокачественного заболевания
CR20230528A (es) Anticuerpo anti componente del complemento 1s (c1s)
BR112021024401A2 (pt) Anticorpos anti-tnf, composições e métodos para o tratamento de espondilite anquilosante ativa
WO2015191610A3 (en) Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways
MA48241A1 (fr) Anticorps dirigés contre madcam
EA202092981A1 (ru) Антитела к l1cam и их применение
WO2015191615A3 (en) Combination therapies using agents that target tumor-associated stroma or tumor cells and alkylating agents
EA202091458A1 (ru) Анти-trem2 антитела и связанные с ними способы